This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
bal fluid | 288 |
pn panel | 288 |
bronchoalveolar lavage | 269 |
respiratory tract | 125 |
cmv dna | 89 |
lower respiratory | 79 |
chronic cough | 69 |
bacterial pneumonia | 69 |
associated pneumonia | 65 |
bal samples | 65 |
bal specimens | 63 |
lavage fluid | 63 |
transplant recipients | 62 |
severe ea | 60 |
lung function | 58 |
il bal | 58 |
hiv infection | 58 |
fluid specimens | 54 |
lung disease | 53 |
respiratory viruses | 53 |
stem cell | 52 |
copies ml | 52 |
airway inflammation | 51 |
cfu ml | 51 |
antibiotic therapy | 50 |
bone marrow | 47 |
acquired pneumonia | 47 |
acute rejection | 47 |
pneumocystis jirovecii | 46 |
presenza di | 46 |
del bal | 45 |
acute respiratory | 43 |
pcr esi | 42 |
risk factors | 42 |
lung transplant | 42 |
intensive care | 42 |
lung biopsy | 41 |
iu ml | 41 |
equine asthma | 40 |
culture results | 39 |
immunocompromised patients | 39 |
cells ml | 39 |
viral infection | 39 |
day mortality | 39 |
cmv pneumonia | 38 |
cell transplantation | 37 |
chain reaction | 37 |
iav infection | 36 |
tmp smx | 36 |
fungal infections | 35 |
polymerase chain | 35 |
adverse events | 35 |
doc id | 34 |
infected individuals | 34 |
infected patients | 34 |
respiratory virus | 34 |
pneumocystis carinii | 34 |
cord uid | 34 |
airway obstruction | 34 |
respiratory syncytial | 33 |
pulmonary infiltrates | 33 |
tracheal aspirate | 33 |
cd counts | 32 |
previously described | 32 |
antiretroviral therapy | 32 |
cell transplant | 31 |
respiratory symptoms | 31 |
respiratory failure | 31 |
syncytial virus | 31 |
hematopoietic stem | 31 |
escalation therapy | 31 |
increased risk | 30 |
fibrinolysis shutdown | 29 |
upper respiratory | 29 |
panel results | 29 |
tract infections | 29 |
nei pazienti | 28 |
diagnostic yield | 28 |
jirovecii pneumonia | 28 |
previous studies | 27 |
infectious diseases | 27 |
airway disease | 27 |
pulmonary disease | 27 |
infected lung | 26 |
antimicrobial therapy | 26 |
severe pjp | 26 |
invasive fungal | 26 |
viral infections | 26 |
bacterial targets | 26 |
eosinophilic alveolitis | 26 |
respiratory disease | 26 |
recurrent airway | 26 |
bacterial culture | 26 |
predictive value | 26 |
lung transplantation | 26 |
respiratory distress | 26 |
marrow transplantation | 25 |
bacterial bronchitis | 25 |
pulmonary complications | 25 |
bal fluids | 25 |
multiplex pcr | 25 |
clinical signs | 25 |
may also | 25 |
routine culture | 25 |
care unit | 25 |
dna load | 24 |
respiratory viral | 24 |
moderate ea | 24 |
del polmone | 24 |
fiberoptic bronchoscopy | 24 |
infiltrative diffuse | 24 |
bal sample | 23 |
distress syndrome | 23 |
thoracic society | 23 |
panel result | 23 |
viral pneumonia | 23 |
immune response | 23 |
mechanical ventilation | 23 |
additional file | 23 |
haemophilus influenzae | 22 |
viral load | 22 |
present study | 22 |
cxcl il | 22 |
pg ml | 22 |
cap cases | 22 |
nucleic acid | 21 |
antibiotic treatment | 21 |
chest radiograph | 21 |
di un | 21 |
positive bal | 21 |
hematopoietic cell | 21 |
carinii pneumonia | 21 |
cystic fibrosis | 21 |
critically ill | 21 |
cd cd | 20 |
extracellular traps | 20 |
alveolar macrophages | 20 |
possono essere | 20 |
logistic regression | 20 |
mould active | 20 |
least one | 20 |
wet cough | 20 |
bal neutrophils | 20 |
pazienti con | 20 |
mg dl | 20 |
protracted bacterial | 20 |
bacterial pathogens | 20 |
time pcr | 19 |
pseudomonas aeruginosa | 19 |
bal performed | 19 |
clinical practice | 19 |
culture result | 19 |
blood cd | 19 |
performed using | 19 |
una diagnosi | 19 |
radiological findings | 19 |
asthma exacerbations | 18 |
current study | 18 |
lower airways | 18 |
induced sputum | 18 |
proven probable | 18 |
di cellule | 18 |
several studies | 18 |
cd count | 18 |
pneumonia patients | 18 |
mild ea | 18 |
peripheral blood | 18 |
lung injury | 18 |
molecular methods | 18 |
human metapneumovirus | 18 |
pneumocystis pneumonia | 18 |
sputum specimens | 18 |
cellular analysis | 18 |
mg kg | 18 |
reactive protein | 18 |
wbc count | 18 |
severe asthma | 18 |
staphylococcus aureus | 18 |
aspergillus fumigatus | 18 |
significantly higher | 18 |
biofire filmarray | 18 |
lower airway | 18 |
di una | 18 |
increased mortality | 17 |
study period | 17 |
specimen collection | 17 |
interstitial lung | 17 |
mast cells | 17 |
inflammatory airway | 17 |
eortc msg | 17 |
nel bal | 17 |
respiratory pathogens | 17 |
tract specimens | 17 |
total wbc | 17 |
cohort study | 17 |
active agents | 17 |
epithelial cells | 17 |
bal culture | 17 |
sofa score | 17 |
proteinosi alveolare | 16 |
pcr assays | 16 |
dei casi | 16 |
lung diseases | 16 |
respiratory specimens | 16 |
dna loads | 16 |
statistically significant | 16 |
ng ml | 16 |
chest ct | 16 |
clinically significant | 16 |
neutrophil extracellular | 16 |
pneumocystis spp | 16 |
ets formation | 16 |
clinical presentation | 16 |
negative patients | 16 |
independently associated | 16 |
differential diagnosis | 16 |
risk factor | 16 |
quantitative tracheal | 16 |
flexible bronchoscopy | 16 |
prospective study | 16 |
likelihood ratio | 16 |
antiviral therapy | 16 |
gene expression | 16 |
recent study | 15 |
probable ia | 15 |
patients receiving | 15 |
asthma patients | 15 |
pcr assay | 15 |
pulmonary aspergillosis | 15 |
csf overexpression | 15 |
patients without | 15 |
polmonite interstiziale | 15 |
respiratory samples | 15 |
eosinophilic inflammation | 15 |
hiv disease | 15 |
american thoracic | 15 |
viral detection | 15 |
serum procalcitonin | 15 |
high bal | 15 |
transbronchial biopsies | 15 |
pneumopatie infiltrative | 15 |
within days | 15 |
streptococcus pneumoniae | 15 |
diffuse del | 15 |
rv infection | 15 |
organ failure | 15 |
previously reported | 14 |
receiving mould | 14 |
informed consent | 14 |
high levels | 14 |
chronic wet | 14 |
negative predictive | 14 |
positive patients | 14 |
function testing | 14 |
computed tomography | 14 |
fluid total | 14 |
alcohol intoxication | 14 |
sct recipients | 14 |
potential impact | 14 |
pulmonary function | 14 |
mortality rate | 14 |
biopsia polmonare | 14 |
united states | 14 |
negative results | 14 |
affected horses | 14 |
pulmonary fibrosis | 14 |
control group | 14 |
un aumento | 14 |
significant differences | 14 |
high risk | 14 |
positive results | 14 |
con il | 14 |
nasopharyngeal swab | 14 |
differential cell | 14 |
among patients | 14 |
exact test | 14 |
tract infection | 14 |
da farmaci | 14 |
human rhinovirus | 13 |
viral pathogens | 13 |
bal sampling | 13 |
virus infection | 13 |
genomic copies | 13 |
diseases society | 13 |
macrofagi alveolari | 13 |
clinical data | 13 |
weight loss | 13 |
antimicrobial stewardship | 13 |
ct scan | 13 |
clinical features | 13 |
general population | 13 |
clinical disease | 13 |
immunosuppressed patients | 13 |
lymphocyte counts | 13 |
cellule di | 13 |
intubated patients | 13 |
bacterial infections | 13 |
allogeneic hematopoietic | 13 |
transbronchial biopsy | 13 |
invasive aspergillosis | 13 |
per milliliter | 13 |
severe pneumonia | 13 |
lrt infection | 13 |
diagnosi di | 13 |
underlying disease | 13 |
fluid samples | 13 |
biopsy specimens | 13 |
lrt detection | 13 |
blood cultures | 12 |
clinical outcomes | 12 |
bacterial species | 12 |
cap group | 12 |
filmarray pneumonia | 12 |
induced asthma | 12 |
poor performance | 12 |
invasive pulmonary | 12 |
chart review | 12 |
molecular assays | 12 |
icu patients | 12 |
csf levels | 12 |
cell counts | 12 |
il lavaggio | 12 |
tracheal mucus | 12 |
microbiologic yield | 12 |
idiopathic pulmonary | 12 |
experienced physician | 12 |
marrow transplant | 12 |
empirical antibiotic | 12 |
fungal pathogens | 12 |
two groups | 12 |
influenza virus | 12 |
hiv patients | 12 |
glucocorticoid therapy | 12 |
severe equine | 12 |
viral targets | 12 |
advanced hiv | 12 |
pneumonia panel | 12 |
pcr testing | 12 |
relative abundance | 12 |
mycoplasma pneumoniae | 12 |
normally distributed | 12 |
study group | 12 |
pulmonary infection | 12 |
bin result | 12 |
smooth muscle | 12 |
diagnostic tool | 12 |
retrospective study | 12 |
lavage samples | 12 |
bacterial target | 12 |
nel dei | 11 |
herpes simplex | 11 |
bal gm | 11 |
reference interval | 11 |
immunodeficiency virus | 11 |
bacterial infection | 11 |
adult patients | 11 |
polmonite da | 11 |
sputum samples | 11 |
upper airway | 11 |
human immunodeficiency | 11 |
influenza infection | 11 |
lavaggio broncoalveolare | 11 |
respiratory infection | 11 |
blood samples | 11 |
clinical response | 11 |
statistical analysis | 11 |
opportunistic infections | 11 |
bal results | 11 |
che il | 11 |
cd lymphocyte | 11 |
macrophage polarization | 11 |
human asthma | 11 |
bal hnp | 11 |
parainfluenza virus | 11 |
healthy horses | 11 |
quantitative pcr | 11 |
minimum database | 11 |
blood culture | 11 |
interstitial pneumonia | 11 |
che non | 11 |
molecular detection | 11 |
clinical symptoms | 11 |
secondary prophylaxis | 11 |
significantly associated | 11 |
solid organ | 11 |
bronchiolitis obliterans | 11 |
cxcl gro | 11 |
fungal infection | 11 |
respiratory support | 11 |
nella diagnosi | 11 |
positive likelihood | 11 |
polmonite eosinofila | 11 |
antibiotic resistance | 11 |
transplant patients | 11 |
cutoff value | 11 |
obstructive pulmonary | 10 |
isolation rates | 10 |
pulmonary infections | 10 |
pure culture | 10 |
viral co | 10 |
controlled trial | 10 |
respiratory infections | 10 |
alcohol consumption | 10 |
etiologic diagnosis | 10 |
bal procedure | 10 |
parainfluenza viruses | 10 |
mac infection | 10 |
di materiale | 10 |
di malattia | 10 |
clinical characteristics | 10 |
among children | 10 |
di polmonite | 10 |
proven cmv | 10 |
infectious pulmonary | 10 |
bal eosinophilia | 10 |
obtained using | 10 |
icu pneumonia | 10 |
specimens obtained | 10 |
contesto clinico | 10 |
bal input | 10 |
diagnostic methods | 10 |
alveolare diffuso | 10 |
infiltrati polmonari | 10 |
side effects | 10 |
copies per | 10 |
decision making | 10 |
pulmonary screening | 10 |
da un | 10 |
deep nasopharyngeal | 10 |
bal specimen | 10 |
pneumonia group | 10 |
prospectively collected | 10 |
cellule epiteliali | 10 |
negative culture | 10 |
counts cells | 10 |
see table | 10 |
blood gas | 10 |
il paziente | 10 |
persistent cough | 10 |
open lung | 10 |
negative bal | 10 |
dei pazienti | 10 |
targets detected | 10 |
fluid cellular | 10 |
low cd | 10 |
even though | 10 |
danno alveolare | 10 |
molecular diagnostic | 10 |
tracheal wash | 10 |
endoscopia bronchiale | 10 |
day post | 10 |
ill patients | 10 |
deve essere | 10 |
airway macrophages | 10 |
ct values | 10 |
confidence interval | 10 |
clinical diagnosis | 9 |
elevated aga | 9 |
reference culture | 9 |
laboratory findings | 9 |
clinical performance | 9 |
adult respiratory | 9 |
underwent bal | 9 |
chronic obstructive | 9 |
eosinophilic pneumonia | 9 |
sample size | 9 |
anche se | 9 |
devono essere | 9 |
diagnostic accuracy | 9 |
bal cytology | 9 |
significant association | 9 |
clinical trial | 9 |
clinical evaluation | 9 |
cmv pneumonitis | 9 |
bronchoscopic bal | 9 |
severe disease | 9 |
punto di | 9 |
ventilatorassociated pneumonia | 9 |
three times | 9 |
immune system | 9 |
di bal | 9 |
study found | 9 |
adverse event | 9 |
atopic children | 9 |
lm mice | 9 |
fob plus | 9 |
delle malattie | 9 |
malattie infiltrative | 9 |
antibiotic regimen | 9 |
case report | 9 |
cellule cd | 9 |
bal within | 9 |
fluid cytology | 9 |
physician performing | 9 |
antimicrobial peptides | 9 |
mouse model | 9 |
lung infection | 9 |
fungal species | 9 |
preweaned calves | 9 |
virus infections | 9 |
test results | 9 |
gold standard | 9 |
prognostic factors | 9 |
lung tissue | 9 |
di langerhans | 9 |
count cells | 9 |
asthmatic patients | 9 |
patient population | 9 |
del balf | 9 |
host disease | 9 |
atypical bacteria | 9 |
arterial blood | 9 |
meca mecc | 9 |
factors associated | 9 |
chest radiographs | 9 |
results obtained | 9 |
radiographic abnormalities | 9 |
bal non | 9 |
ml vs | 9 |
np aspirate | 9 |
cytomegalovirus infection | 9 |
recent studies | 9 |
consensus statement | 9 |
filmarray respiratory | 9 |
caso di | 9 |
input concentration | 9 |
neutrophilic inflammation | 9 |
underlying conditions | 9 |
cell count | 9 |
body weight | 9 |
positive predictive | 9 |
capitolo endoscopia | 9 |
developed world | 9 |
cmv dnaemia | 9 |
plus bal | 9 |
specimen types | 9 |
vie aeree | 9 |
myeloid cells | 9 |
polmonare idiopatica | 9 |
positive cultures | 9 |
procalcitonin concentration | 9 |
delle cellule | 8 |
diagnostiche invasive | 8 |
endotracheal aspirates | 8 |
triggering receptor | 8 |
mild asthma | 8 |
viral agents | 8 |
procedure diagnostiche | 8 |
infectious agents | 8 |
antibiotic stewardship | 8 |
antifungal treatment | 8 |
united kingdom | 8 |
molecular tests | 8 |
distributed data | 8 |
dna extraction | 8 |
disseminated infection | 8 |
nasal discharge | 8 |
nasopharyngeal swabs | 8 |
high sensitivity | 8 |
fibrinolysis phenotypes | 8 |
one case | 8 |
prospective studies | 8 |
della biopsia | 8 |
fibrosi polmonare | 8 |
molecular tools | 8 |
numero di | 8 |
dei linfociti | 8 |
neutrophilic airway | 8 |
hct recipients | 8 |
health care | 8 |
si possono | 8 |
alveolar lavage | 8 |
di esecuzione | 8 |
good quality | 8 |
young children | 8 |
pazienti immunocompromessi | 8 |
soc culture | 8 |
sedimento del | 8 |
pjp diagnosis | 8 |
day compared | 8 |
pediatric cap | 8 |
interstitial infiltration | 8 |
table ii | 8 |
continuous variables | 8 |
linfangite carcinomatosa | 8 |
systemic inflammation | 8 |
transbronchial lung | 8 |
categorical variables | 8 |
data collection | 8 |
sct patients | 8 |
group i | 8 |
simplex virus | 8 |
negative likelihood | 8 |
non si | 8 |
asthma phenotypes | 8 |
ml di | 8 |
cxc chemokines | 8 |
che si | 8 |
le pinze | 8 |
pulmonary cmv | 8 |
fungal disease | 8 |
stimulating factor | 8 |
acute physiology | 8 |
cavalier king | 8 |
di neutrofili | 8 |
clinical significance | 8 |
antimicrobial treatment | 8 |
significantly increased | 8 |
king charles | 8 |
lung lesions | 8 |
patients whose | 8 |
regression analysis | 8 |
susceptibility testing | 8 |
soluble triggering | 8 |
canale operativo | 8 |
nelle pneumopatie | 8 |
north america | 8 |
soc results | 8 |
airway remodeling | 8 |
glass appearance | 8 |
cxcl nap | 8 |
receptor expressed | 8 |
mortality rates | 8 |
viral culture | 8 |
molecular testing | 8 |
cough variant | 8 |
acute lung | 8 |
protein concentration | 8 |
variant asthma | 8 |
oral flora | 8 |
four different | 8 |
pleural fluid | 8 |
di per | 8 |
clinically relevant | 8 |
interstitial infiltrates | 8 |
standard deviation | 8 |
proposed minimum | 8 |
commonly identified | 8 |
middle lobe | 8 |
mass spectrometry | 8 |
allogeneic bone | 8 |
patient outcomes | 8 |
con una | 8 |
results may | 8 |
diagnostic test | 8 |
study population | 8 |
pediatric patients | 8 |
circulating immune | 8 |
independent molecular | 8 |
esi ms | 8 |
allograft rejection | 8 |
two patients | 8 |
respiratory panel | 8 |
aspergillus pcr | 8 |
dtgm mice | 8 |
panel detected | 8 |
simplified acute | 8 |
infect dis | 8 |
corso di | 8 |
nei casi | 8 |
per day | 8 |
pathway analysis | 8 |
cell type | 7 |
appropriate antibiotic | 7 |
immunocompromised children | 7 |
ahsct recipients | 7 |
nella polmonite | 7 |
una procedura | 7 |
drug interactions | 7 |
pneumonia cases | 7 |
panel test | 7 |
pneumocystis jiroveci | 7 |
patients undergoing | 7 |
invasive mechanical | 7 |
immune complexes | 7 |
una biopsia | 7 |
common cause | 7 |
pleural effusion | 7 |
blood cell | 7 |
respiratory sample | 7 |
airway smooth | 7 |
electrospray ionization | 7 |
gastroesophageal reflux | 7 |
one study | 7 |
aumento dei | 7 |
group ii | 7 |
human coronavirus | 7 |
one third | 7 |
di linfociti | 7 |
physiologic levels | 7 |
non sono | 7 |
authors declare | 7 |
moraxella catarrhalis | 7 |
inflammatory mediators | 7 |
acute phase | 7 |
hematologic malignancies | 7 |
care units | 7 |
flow nasal | 7 |
polmonare chirurgica | 7 |
blood alcohol | 7 |
questi pazienti | 7 |
organ transplantation | 7 |
determine whether | 7 |
initial treatment | 7 |
acute eosinophilic | 7 |
clot formation | 7 |
control subjects | 7 |
opportunistic infection | 7 |
tract swabs | 7 |
airway neutrophilia | 7 |
virus load | 7 |
current guidelines | 7 |
interquartile range | 7 |
physiology score | 7 |
multivariate analysis | 7 |
semiquantitative results | 7 |
mpo activity | 7 |
may provide | 7 |
positivity rate | 7 |
patient care | 7 |
treatment failure | 7 |
se il | 7 |
quantitative culture | 7 |
blood pressure | 7 |
aumento della | 7 |
one specimen | 7 |
urt testing | 7 |
ratio cd | 7 |
suspected ventilator | 7 |
negative detections | 7 |
increased expression | 7 |
respiratory diseases | 7 |
hospitalized patients | 7 |
discordant results | 7 |
msg criteria | 7 |
inflammatory response | 7 |
negative upper | 7 |
per una | 7 |
bal levels | 7 |
il broncoscopio | 7 |
immune deficiency | 7 |
clone libraries | 7 |
exhaled breath | 7 |
di macrofagi | 7 |
dna quantitation | 7 |
herd effect | 7 |
regression model | 7 |
nel caso | 7 |
specimens tested | 7 |
adjuvant glucocorticoid | 7 |
results reported | 7 |
nonatopic children | 7 |
forming units | 7 |
flow cytometry | 7 |
quando il | 7 |
diagnostic criteria | 7 |
chest radiographic | 7 |
potential pathogens | 7 |
multicenter evaluation | 7 |
malattie diffuse | 7 |
another study | 7 |
icu admission | 7 |
disease progression | 7 |
indice di | 7 |
negative specimens | 7 |
patients may | 7 |
patients received | 7 |
clinical trials | 7 |
children without | 7 |
infectious disease | 7 |
influenza viruses | 7 |
casi di | 7 |
aerobic bacteria | 7 |
citrullinated histone | 7 |
may occur | 7 |
low levels | 7 |
rendimento diagnostico | 7 |
virus detection | 7 |
il liquido | 7 |
dna shedding | 7 |
high rates | 7 |
antimicrobial resistance | 7 |
fluid recovered | 7 |
percent agreement | 7 |
study design | 7 |
polmoniti da | 7 |
normal controls | 7 |
pneumonia episodes | 7 |
normal oral | 6 |
prima aliquota | 6 |
see earlier | 6 |
recipient cmv | 6 |
i dati | 6 |
diffuse lung | 6 |
clinical impact | 6 |
within day | 6 |
biopsia chirurgica | 6 |
pulmonary tuberculosis | 6 |
pcr amplification | 6 |
positive culture | 6 |
study showed | 6 |
alveolar proteinosis | 6 |
findings suggest | 6 |
diagnostic information | 6 |
tract viral | 6 |
di organizzazione | 6 |
sedimento di | 6 |
conta differenziale | 6 |
disseminated mac | 6 |
rapid diagnosis | 6 |
median cmv | 6 |
nel balf | 6 |
asthmatic subjects | 6 |
alveolitis profile | 6 |
may lead | 6 |
positive viral | 6 |
lavage bronchoalveolar | 6 |
radiological lesions | 6 |
common cold | 6 |
immune cells | 6 |
caratterizzato da | 6 |
innate immune | 6 |
institutional review | 6 |
two cases | 6 |
dendritic cell | 6 |
bal cultures | 6 |
needle aspiration | 6 |
reverse transcriptase | 6 |
increased incidence | 6 |
esecuzione del | 6 |
nonendoscopic bal | 6 |
prospective cohort | 6 |
quantitative cultures | 6 |
negative result | 6 |
hiv immunocompromised | 6 |
data suggest | 6 |
eseguire il | 6 |
antimicrobial agents | 6 |
nosocomial pneumonia | 6 |
commonly used | 6 |
odds ratio | 6 |
molecular approaches | 6 |
wide range | 6 |
hsct recipients | 6 |
detected using | 6 |
i linfociti | 6 |
core fungi | 6 |
ma non | 6 |
cough resolution | 6 |
significant difference | 6 |
acute graft | 6 |
ha un | 6 |
aspiration pneumonia | 6 |
haematological malignancies | 6 |
diagnostic procedures | 6 |
di malattie | 6 |
culture methods | 6 |
roc curve | 6 |
taken together | 6 |
severe acute | 6 |
di vista | 6 |
positive pairs | 6 |
hct candidates | 6 |
resa diagnostica | 6 |
lower tract | 6 |
ingenuity pathway | 6 |
high rate | 6 |
cmv pcr | 6 |
included patients | 6 |
mechanically ventilated | 6 |
cumulative incidence | 6 |
injured patient | 6 |
blood eosinophilia | 6 |
two different | 6 |
appropriate treatment | 6 |
spectrum beta | 6 |
infection prevention | 6 |
within hours | 6 |
un ruolo | 6 |
infiltrates following | 6 |
trend towards | 6 |
opportunistic disease | 6 |
healthy children | 6 |
virus detected | 6 |
ventilated patients | 6 |
positive specimens | 6 |
less frequently | 6 |
considered positive | 6 |
thrombotic complications | 6 |
organizing pneumonia | 6 |
children aged | 6 |
antimicrobial susceptibility | 6 |
total number | 6 |
cell line | 6 |
curve analysis | 6 |
oxygen therapy | 6 |
da tbb | 6 |
invasive ventilation | 6 |
antifungal resistance | 6 |
resistant staphylococcus | 6 |
supplementary table | 6 |
using routine | 6 |
bronchiale diagnostica | 6 |
spectrum reduction | 6 |
among hiv | 6 |
reference lab | 6 |
white blood | 6 |
recurrent episodes | 6 |
ad un | 6 |
false positive | 6 |
acid extraction | 6 |
human medicine | 6 |
bal cxcl | 6 |
lrt testing | 6 |
selective media | 6 |
kaposi sarcoma | 6 |
critical revision | 6 |
semiquantitative bin | 6 |
nelle malattie | 6 |
diagnostic testing | 6 |
disease bronchoalveolar | 6 |
dis doi | 6 |
values reported | 6 |
cell types | 6 |
clinical suspicion | 6 |
mean age | 6 |
legionella pneumophila | 6 |
asthma severity | 6 |
pnplus panel | 6 |
nel bronco | 6 |
massive transfusion | 6 |
british racing | 6 |
lymph node | 6 |
mixed infections | 6 |
il riscontro | 6 |
respiratory pathogen | 6 |
rhinovirus infections | 6 |
british thoracic | 6 |
zoster virus | 6 |
del paziente | 6 |
small number | 6 |
supplementary material | 6 |
count ml | 6 |
less likely | 6 |
antigen testing | 6 |
fumigatus qpcr | 6 |
vi sono | 6 |
charles spaniel | 6 |
review board | 6 |
online resource | 6 |
north american | 6 |
shutdown compared | 6 |
healthy animals | 6 |
polmonite lipoidea | 6 |
new pulmonary | 6 |
clinical presentations | 6 |
cd cells | 6 |
consensus guidelines | 6 |
diagnostic value | 6 |
grade adverse | 6 |
airway hyperresponsiveness | 6 |
significantly different | 6 |
biofire diagnostics | 6 |
inhaled corticosteroids | 6 |
patients admitted | 6 |
icu stay | 6 |
pulmonary work | 6 |
gas analysis | 6 |
time point | 6 |
linear regression | 6 |
amr gene | 6 |
independent predictor | 6 |
invasive nelle | 6 |
biofire pn | 6 |
exudative macrophages | 6 |
conducted using | 6 |
bal di | 6 |
cmv seropositivity | 6 |
azole resistance | 6 |
tipo di | 6 |
clinical utility | 6 |
lavage cell | 6 |
total lung | 6 |
failure assessment | 6 |
grunwald giemsa | 6 |
polymicrobial nature | 6 |
lymphocyte count | 6 |
rdna gene | 6 |
di pazienti | 6 |
dns culture | 6 |
antibiotic adjustments | 6 |
diagnostic tests | 6 |
adverse reactions | 6 |
remained negative | 6 |
allergic asthma | 6 |
graft rejection | 6 |
medical records | 6 |
human respiratory | 6 |
analyzed using | 6 |
respiratory signs | 6 |
tranexamic acid | 6 |
polymicrobial dns | 6 |
patient outcome | 6 |
square test | 6 |
statistical significance | 6 |
da cellule | 5 |
sequential organ | 5 |
pretest clinical | 5 |
alveolite emorragica | 5 |
observational study | 5 |
least two | 5 |
su pazienti | 5 |
using standard | 5 |
whole population | 5 |
bal viral | 5 |
di origine | 5 |
infectious etiologies | 5 |
room temperature | 5 |
viral nucleic | 5 |
experimental rhinovirus | 5 |
current treatment | 5 |
forced expiratory | 5 |
ethics committee | 5 |
materiale alimentare | 5 |
upper lobe | 5 |
advisory board | 5 |
equine model | 5 |
pulmonary diseases | 5 |
urinary antigen | 5 |
roche diagnostics | 5 |
may contribute | 5 |
reaction testing | 5 |
specimens collected | 5 |
pulmonary alveolar | 5 |
asthma subjects | 5 |
serum aga | 5 |
two independent | 5 |
chlamydophila pneumoniae | 5 |
cmv infection | 5 |
dei neutrofili | 5 |
della procedura | 5 |
immune reconstitution | 5 |
drug therapy | 5 |
mycoses study | 5 |
plasminogen activator | 5 |
may present | 5 |
high concentrations | 5 |
european organization | 5 |
worse sofa | 5 |
lavage specimens | 5 |
protein levels | 5 |
antifungal therapy | 5 |
reference laboratory | 5 |
sample pairs | 5 |
airway gm | 5 |
viral respiratory | 5 |
type ii | 5 |
matrix metalloproteinase | 5 |
acute alcohol | 5 |
di solito | 5 |
epa exacerbation | 5 |
antigen detection | 5 |
essere di | 5 |
procedure invasive | 5 |
normal subjects | 5 |
laboratory results | 5 |
official american | 5 |
broncoalveolare nelle | 5 |
confidence intervals | 5 |
pure cultures | 5 |
chronic suppurative | 5 |
predicting bacterial | 5 |
see tables | 5 |
fluid culture | 5 |
serum samples | 5 |
reverse transcription | 5 |
inverse correlation | 5 |
riscontro di | 5 |
mycological criteria | 5 |
widely used | 5 |
calculated using | 5 |
lo studio | 5 |
scoring system | 5 |
low bal | 5 |
systematic review | 5 |
specimens using | 5 |
one bal | 5 |
active tuberculosis | 5 |
ad una | 5 |
lung capacity | 5 |
bal bacterial | 5 |
si osservano | 5 |
apache ii | 5 |
inflammatory process | 5 |
alternative diagnosis | 5 |
many patients | 5 |
sample collection | 5 |
rejection episodes | 5 |
clinical specimens | 5 |
resolution computed | 5 |
bacterial communities | 5 |
severe respiratory | 5 |
reference methods | 5 |
severe pcp | 5 |
tuberculosis infection | 5 |
della mucosa | 5 |
questi casi | 5 |
upper airways | 5 |
national institute | 5 |
statistical analyses | 5 |
il numero | 5 |
endothelial cell | 5 |
dna detection | 5 |
emorragia alveolare | 5 |
oral tmp | 5 |
monoclonal antibodies | 5 |
risk patients | 5 |
cui si | 5 |
candida species | 5 |
extracellular trap | 5 |
hematological malignancy | 5 |
predictive values | 5 |
di attivazione | 5 |
con broncoscopio | 5 |
hiv rna | 5 |
lamina propria | 5 |
remaining patients | 5 |
pneumonia pneumocystis | 5 |
percentuale dei | 5 |
atypical ia | 5 |
chest pain | 5 |
following bone | 5 |
physiologic fibrinolysis | 5 |
fungal culture | 5 |
dna levels | 5 |
linear mixed | 5 |
allogeneic stem | 5 |
specimens containing | 5 |
bal neutrophil | 5 |
practice guidelines | 5 |
panel bacterial | 5 |
di soluzione | 5 |
years old | 5 |
che hanno | 5 |
treatment regimens | 5 |
time points | 5 |
il recupero | 5 |
expectorated sputum | 5 |
jirovecii prophylaxis | 5 |
randomized controlled | 5 |
see later | 5 |
asthmatic group | 5 |
specifically designed | 5 |
panel demonstrated | 5 |
acid detection | 5 |
retrospective analysis | 5 |
diffusa del | 5 |
serological testing | 5 |
lung rejection | 5 |
respiratory medicine | 5 |
studies performed | 5 |
natural history | 5 |
may help | 5 |
lactate dehydrogenase | 5 |
ml kg | 5 |
molecular assay | 5 |
polmonare da | 5 |
trauma patients | 5 |
cerebrospinal fluid | 5 |
pasture asthma | 5 |
pazienti immunocompetenti | 5 |
diffuse alveolar | 5 |
hospital stay | 5 |
muscle mass | 5 |
patient characteristics | 5 |
elafin levels | 5 |
malattia da | 5 |
attraverso il | 5 |
univariate analysis | 5 |
anaerobic bacteria | 5 |
dei macrofagi | 5 |
microscopic examination | 5 |
inflammatory diseases | 5 |
biologia molecolare | 5 |
specific primers | 5 |
positive bacterial | 5 |
rapporto cd | 5 |
nella nostra | 5 |
one bacterium | 5 |
chronic airway | 5 |
differential expression | 5 |
america american | 5 |
general anesthesia | 5 |
malattia interstiziale | 5 |
positive result | 5 |
partial pressure | 5 |
higher levels | 5 |
hrct findings | 5 |
di esposizione | 5 |
large number | 5 |
del liquido | 5 |
median days | 5 |
dalla presenza | 5 |
mixed infection | 5 |
data demonstrate | 5 |
respiratory health | 5 |
multicenter study | 5 |
epithelial cell | 5 |
negative agreement | 5 |
alternate diagnoses | 5 |
cmv therapy | 5 |
bal cells | 5 |
cellular profiles | 5 |
reactive oxygen | 5 |
respiratory rate | 5 |
possible fungal | 5 |
haemophilus haemolyticus | 5 |
via di | 5 |
patients date | 5 |
della metodica | 5 |
society consensus | 5 |
della malattia | 5 |
versus host | 5 |
expiratory volume | 5 |
airway malacia | 5 |
folinic acid | 5 |
interval ci | 5 |
nel sedimento | 5 |
lysosomal enzyme | 5 |
related pneumonia | 5 |
mucosa bronchiale | 5 |
barrier function | 5 |
developing world | 5 |
empirical therapy | 5 |
di tessuto | 5 |
magna pure | 5 |
di queste | 5 |
nasal lavage | 5 |
diffuse interstitial | 5 |
nucleic acids | 5 |
targets quantified | 5 |
resolution ct | 5 |
received antimicrobial | 5 |
quota di | 5 |
frequently detected | 5 |
empiric antibiotic | 5 |
elevated serum | 5 |
macrophage colony | 5 |
infection may | 5 |
genetic markers | 5 |
although bal | 5 |
con un | 5 |
also performed | 5 |
patient populations | 5 |
respiratory syndrome | 5 |
recent years | 5 |
quality control | 5 |
relatively low | 5 |
attending physicians | 5 |
medical center | 5 |
emergency department | 5 |
causative agents | 5 |
dendritic cells | 5 |
elevated levels | 5 |
targets reported | 5 |
broncoscopio rigido | 5 |
quantitative reference | 5 |
frequently associated | 5 |
pao fio | 5 |
inflammatory markers | 5 |
saline solution | 5 |
causative pathogen | 5 |
organic dust | 5 |
lobo medio | 5 |
asthma exacerbation | 5 |
influenzae type | 5 |
diagnosi specifica | 5 |
mycobacterial disease | 5 |
possible ia | 5 |
nella proteinosi | 5 |
md declares | 5 |
rrna gene | 5 |
patients included | 5 |
chronic respiratory | 5 |
surfactant protein | 5 |
hypersensitivity pneumonitis | 5 |
compared using | 5 |
bacterial cultures | 5 |
also important | 5 |
johns hopkins | 5 |
cellule neoplastiche | 5 |
fluid analysis | 5 |
electron microscopy | 5 |
thoroughbred racehorses | 5 |
aspergillus species | 5 |
bacterial clone | 5 |
pulmonary fungal | 5 |
equine recurrent | 5 |
signaling pathways | 5 |
immunocompromised adults | 5 |
horses affected | 5 |
clinical findings | 5 |
circa il | 5 |
commercially available | 5 |
may play | 5 |
early risk | 5 |
equine heaves | 5 |
right middle | 5 |
empirical treatment | 5 |
amr genes | 5 |
nostra esperienza | 5 |
neutrophilic asthma | 5 |
nonproductive cough | 5 |
rhinovirus infection | 5 |
high frequency | 5 |
sputum cultures | 5 |
mg day | 5 |
enzyme release | 5 |
hematology patients | 5 |
patients assigned | 5 |
preceding specimen | 5 |
bacterial pathogen | 5 |
lrt sample | 5 |
studies suggest | 5 |
lavage findings | 5 |
chest hrct | 5 |
panel testing | 5 |
fewer drugs | 5 |
tecniche di | 5 |
i macrofagi | 5 |
innate lymphoid | 5 |
peso corporeo | 5 |
immunocompromised state | 5 |
international standard | 5 |
asthma group | 5 |
il ruolo | 5 |
trap formation | 5 |
chronic inflammatory | 5 |
qualora si | 5 |
bacterial isolates | 5 |
soluzione fisiologica | 5 |
positive mycological | 5 |
soggetti con | 5 |
graft versus | 5 |
immunocompromised host | 5 |
fisher exact | 4 |
fenotipo cd | 4 |
enzyme immunoassay | 4 |
atopic asthma | 4 |
clinical bal | 4 |
considered significant | 4 |
lethal influenza | 4 |
negative percent | 4 |
line prophylactic | 4 |
pathogens identified | 4 |
lavage cellularity | 4 |
per year | 4 |
intravenous pentamidine | 4 |
corresponding library | 4 |
polmonare transbronchiale | 4 |
serum il | 4 |
group discussions | 4 |
pcp prophylaxis | 4 |
reference intervals | 4 |
campioni ottenuti | 4 |
fumigatus real | 4 |
di langherans | 4 |
lrt involvement | 4 |
ets release | 4 |
gram stain | 4 |
inflammatory cells | 4 |
noninfectious inflammatory | 4 |
pathogens present | 4 |
roc analysis | 4 |
body mass | 4 |
cell cycle | 4 |
histamine bronchoprovocation | 4 |
study included | 4 |
diametro esterno | 4 |
aumento di | 4 |
essere considerata | 4 |
standard oxygen | 4 |
di churg | 4 |
one bacterial | 4 |
age years | 4 |
comparator method | 4 |
medical history | 4 |
bal testing | 4 |
lobulo polmonare | 4 |
four times | 4 |
prospective clinical | 4 |
alla biopsia | 4 |
risk balance | 4 |
two separate | 4 |
tract samples | 4 |
che le | 4 |
invasive procedures | 4 |
medical record | 4 |
focus group | 4 |
older age | 4 |
polymicrobial specimens | 4 |
significant inverse | 4 |
cancer invasive | 4 |
saps ii | 4 |
immunosorbent assay | 4 |
bovine respiratory | 4 |
summer pasture | 4 |
communityacquired pneumonia | 4 |
di balf | 4 |
nasal cavity | 4 |
natural killer | 4 |
diseases mycoses | 4 |
autoimmune diseases | 4 |
direct examination | 4 |
less effective | 4 |
positive lrt | 4 |
barr virus | 4 |
oxygen saturations | 4 |
fold higher | 4 |
diagnostica della | 4 |
failure requiring | 4 |
patients showed | 4 |
current culture | 4 |
previously identified | 4 |
heart disease | 4 |
direct immunofluorescence | 4 |
alla diagnosi | 4 |
fibrinolytic phenotype | 4 |
recurrent bacterial | 4 |
rejection grade | 4 |
tmp smz | 4 |
otitis media | 4 |
provide useful | 4 |
critically revised | 4 |
pazienti ventilati | 4 |
bacterial analytes | 4 |
hct pulmonary | 4 |
mycoplasma bovis | 4 |
may require | 4 |
first study | 4 |
negative test | 4 |
fungal dna | 4 |
found evidence | 4 |
accurate bin | 4 |
clinical severity | 4 |
liver disease | 4 |
improve patient | 4 |
median age | 4 |
immune responses | 4 |
bal eosinophils | 4 |
pjp patients | 4 |
pulse oximetry | 4 |
antituberculosis therapy | 4 |
hematological malignancies | 4 |
anche essere | 4 |
polmonare secondario | 4 |
like particles | 4 |
ms assay | 4 |
bal tolerance | 4 |
neutrophil percentage | 4 |
recipients undergoing | 4 |
il cui | 4 |
th cells | 4 |
un valore | 4 |
preemptive therapy | 4 |
cell suspensions | 4 |
monoclonal antibody | 4 |
antibiotic treatments | 4 |
bal measured | 4 |
protected brush | 4 |
reportable range | 4 |
pr iav | 4 |
positive pcr | 4 |
mrna expression | 4 |
di biologia | 4 |
penn state | 4 |
multicenter cohort | 4 |
treatment changes | 4 |
coccidioides species | 4 |
host defense | 4 |
year study | 4 |
versus lower | 4 |
internal medicine | 4 |
dei lipofagi | 4 |
microbiology laboratory | 4 |
ventilati meccanicamente | 4 |
hanno riportato | 4 |
mask airway | 4 |
little evidence | 4 |
interpreted data | 4 |
cytological examination | 4 |
dna traps | 4 |
non vi | 4 |
first bal | 4 |
alveolar consolidation | 4 |
target fungi | 4 |
study assessed | 4 |
endemic areas | 4 |
nel giusto | 4 |
may arise | 4 |
infection due | 4 |
antipseudomonal beta | 4 |
patients requiring | 4 |
neg dim | 4 |
definitive diagnosis | 4 |
bronchial obstruction | 4 |
flexible fiberoptic | 4 |
based methods | 4 |
macrofagi schiumosi | 4 |
pneumonia requiring | 4 |
di infiltrati | 4 |
thermo fisher | 4 |
fisher scientific | 4 |
oral valganciclovir | 4 |
routine soc | 4 |
accanto ad | 4 |
esami colturali | 4 |
pathogens associated | 4 |
viral pcr | 4 |
disease associated | 4 |
materiale amorfo | 4 |
aspergillus infection | 4 |
di ricerca | 4 |
tissue damage | 4 |
autori hanno | 4 |
da reflusso | 4 |
blood gases | 4 |
human cytomegalovirus | 4 |
quantitative polymerase | 4 |
detailed data | 4 |
nasal oxygen | 4 |
pcp may | 4 |
future research | 4 |
inclusion criteria | 4 |
result reporting | 4 |
hfnc therapy | 4 |
clinical parameters | 4 |
positive multiplex | 4 |
airway infection | 4 |
del lobo | 4 |
distributed variables | 4 |
ad eseguire | 4 |
ct value | 4 |
attributable mortality | 4 |
infected individual | 4 |
elevated gm | 4 |
task force | 4 |
bin results | 4 |
temporal relationship | 4 |
similar results | 4 |
nasal cannula | 4 |
bal si | 4 |
samples containing | 4 |
novel phylotypes | 4 |
nasopharyngeal samples | 4 |
queste considerazioni | 4 |
asthmatics compared | 4 |
indagini microbiologiche | 4 |
receiver operating | 4 |
prophylaxis may | 4 |
bal aga | 4 |
patients exhibited | 4 |
study reported | 4 |
tubo tracheale | 4 |
con aspetti | 4 |
targeted therapy | 4 |
increased percentage | 4 |
bronchial epithelium | 4 |
diagnostic bronchoscopy | 4 |
single cell | 4 |
di grasso | 4 |
currently available | 4 |
bacterial phylotypes | 4 |
pneumociti di | 4 |
endotracheal aspirate | 4 |
multiplex molecular | 4 |
exclusion criteria | 4 |
new respiratory | 4 |
escherichia coli | 4 |
danno polmonare | 4 |
common respiratory | 4 |
hypoxemic respiratory | 4 |
low incidence | 4 |
trauma activation | 4 |
laryngeal mask | 4 |
mass index | 4 |
lavage cytology | 4 |
function tests | 4 |
ventilazione meccanica | 4 |
adverse effects | 4 |
log bin | 4 |
tracheal aspirates | 4 |
infected subjects | 4 |
alveolar hemorrhage | 4 |
anestesia generale | 4 |
un catetere | 4 |
recent advances | 4 |
clin microbiol | 4 |
rare cells | 4 |
antibiotic use | 4 |
also provided | 4 |
esecuzione della | 4 |
financial support | 4 |
pathogen detection | 4 |
target bacteria | 4 |
respiratory society | 4 |
therapy may | 4 |
diagnostico delle | 4 |
breath condensate | 4 |
aspergillus galactomannan | 4 |
genbank database | 4 |
nella malattia | 4 |
veal calves | 4 |
spectrum antimicrobial | 4 |
specific therapy | 4 |
may explain | 4 |
widespread use | 4 |
rhinovirus enterovirus | 4 |
longitudinal study | 4 |
underwent bronchoscopic | 4 |
mycoplasma spp | 4 |
prophylactic agent | 4 |
positive individuals | 4 |
intoxicated patients | 4 |
log copies | 4 |
routine diagnostic | 4 |
significant increase | 4 |
alveolar macrophage | 4 |
previous work | 4 |
trimethoprim sulfamethoxazole | 4 |
linfociti cd | 4 |
coronavirus infections | 4 |
bacterial respiratory | 4 |
increased circulating | 4 |
dominant culture | 4 |
standardbred trotters | 4 |
extracellular dna | 4 |
rather low | 4 |
data indicate | 4 |
ventilator icu | 4 |
arterial oxygen | 4 |
pattern hrct | 4 |
favorable clinical | 4 |
diffuse pulmonary | 4 |
independent determinants | 4 |
ad alta | 4 |
ionization mass | 4 |
antibiotic modifications | 4 |
sterile saline | 4 |
central nervous | 4 |
nei bambini | 4 |
children bronchoalveolar | 4 |
dental plaque | 4 |
hiv infected | 4 |
many centers | 4 |
strength tablet | 4 |
fluid testing | 4 |
therapeutic option | 4 |
operating characteristic | 4 |
inhaled steroids | 4 |
cielo aperto | 4 |
allo stato | 4 |
species level | 4 |
hospitalized children | 4 |
recurrent pbb | 4 |
written informed | 4 |
le vie | 4 |
hodgkin lymphoma | 4 |
conditioning regimen | 4 |
regulatory clearance | 4 |
small airways | 4 |
also cause | 4 |
routine clinical | 4 |
similar findings | 4 |
initial antibiotic | 4 |
malattie polmonari | 4 |
protective effect | 4 |
preemptive antiviral | 4 |
controlled asthma | 4 |
club cells | 4 |
valore prognostico | 4 |
mycobacterium sp | 4 |
pulmonary microbiota | 4 |
pneumonia plus | 4 |
nelle polmoniti | 4 |
liquido instillato | 4 |
lung dysfunction | 4 |
hydrogen peroxide | 4 |
nel work | 4 |
pcr test | 4 |
skin test | 4 |
antibiotic utilization | 4 |
medical icu | 4 |
commonly detected | 4 |
alternative diagnoses | 4 |
permette di | 4 |
antimicrobial agent | 4 |
cytomegalovirus dna | 4 |
recent work | 4 |
significantly lower | 4 |
adversely affect | 4 |
epithelial barrier | 4 |
investigated whether | 4 |
i punti | 4 |
viral loads | 4 |
non specifici | 4 |
degli eosinofili | 4 |
upper versus | 4 |
time polymerase | 4 |
contrived samples | 4 |
project sponsored | 4 |
causative agent | 4 |
per le | 4 |
routinely performed | 4 |
il valore | 4 |
poor quality | 4 |
assessed using | 4 |
per group | 4 |
cfu per | 4 |
radiograph may | 4 |
optimal cutoff | 4 |
hivinfected patients | 4 |
european respiratory | 4 |
nella diagnostica | 4 |
non solo | 4 |
una polmonite | 4 |
bal collection | 4 |
clinical condition | 4 |
mucus accumulation | 4 |
potential conflicts | 4 |
tests performed | 4 |
le cellule | 4 |
latent tuberculosis | 4 |
inspired oxygen | 4 |
equine respiratory | 4 |
blood agar | 4 |
le procedure | 4 |
two thirds | 4 |
antibiotic exposure | 4 |
research directions | 4 |
ground glass | 4 |
di fibrosi | 4 |
among immunocompromised | 4 |
aids patients | 4 |
interferon signaling | 4 |
novel bacterial | 4 |
airway lumen | 4 |
less severe | 4 |
oxygen species | 4 |
hct screening | 4 |
sputum sample | 4 |
also used | 4 |
different types | 4 |
sono quindi | 4 |
normal group | 4 |
steering committee | 4 |
least weeks | 4 |
dati clinici | 4 |
plus panel | 4 |
recurrent cap | 4 |
immunodeficiency syndrome | 4 |
measured using | 4 |
ricerca di | 4 |
will require | 4 |
acquired immunodeficiency | 4 |
appropriate infection | 4 |
patient group | 4 |
state university | 4 |
lung microbiota | 4 |
increased levels | 4 |
underwent bronchoscopy | 4 |
linked immunosorbent | 4 |
detection rate | 4 |
antibiotic escalation | 4 |
mg ml | 4 |
un numero | 4 |
severe pneumocystis | 4 |
non invasive | 4 |
also reported | 4 |
small airway | 4 |
without aids | 4 |
odds ratios | 4 |
previous study | 4 |
combination therapy | 4 |
potential antibiotic | 4 |
also significantly | 4 |
less invasive | 4 |
significantly reduced | 4 |
molecular test | 4 |
pleural effusions | 4 |
cytomegalovirus pneumonia | 4 |
target detected | 4 |
future studies | 4 |
cxcl gcp | 4 |
th th | 4 |
anche un | 4 |
cardiovascular disease | 4 |
exclude covid | 4 |
soc methods | 4 |
panel reported | 4 |
broad spectrum | 4 |
upper limit | 4 |
delle procedure | 4 |
jirovecii infection | 4 |
multinomial logistic | 4 |
per ml | 4 |
ers task | 4 |
suppurative lung | 4 |
survival benefit | 4 |
si osserva | 4 |
unnecessary antibiotics | 4 |
pure lc | 4 |
thank dr | 4 |
adult lung | 4 |
graphpad prism | 4 |
cell profile | 4 |
macrofagi con | 4 |
mast cell | 4 |
diffuse infiltrative | 4 |
higher risk | 4 |
likely related | 4 |
molecular method | 4 |
central reference | 4 |
probable cmv | 4 |
american college | 4 |
prolonged antibiotic | 4 |
aspetti morfologici | 4 |
improved detection | 4 |
lung allograft | 4 |
online version | 4 |
chest radiography | 4 |
pcr results | 4 |
lipid index | 4 |
human neutrophil | 4 |
i pazienti | 4 |
thoracic radiographs | 4 |
sided confidence | 4 |
nonnucleoside rti | 4 |
nasal secretions | 4 |
diagnostic strategy | 4 |
strongly associated | 4 |
false negative | 4 |
laboratory animals | 4 |
pneumopatie diffuse | 4 |
negative bacteria | 4 |
low yield | 4 |
alveolite linfocitaria | 4 |
il lume | 4 |
diagnostico della | 4 |
aliquota del | 4 |
cord blood | 4 |
productive cough | 4 |
il canale | 4 |
non specifiche | 4 |
may affect | 4 |
nel loro | 4 |
bronchiale pediatrica | 4 |
also identified | 4 |
virus type | 4 |
panel assay | 4 |
expressing il | 4 |
steroid therapy | 4 |
positive blood | 4 |
nv icu | 4 |
non specifico | 4 |
non diversamente | 4 |
lower limit | 4 |
bacterial flora | 4 |
different studies | 4 |
resistance markers | 4 |
zona di | 4 |
patients presenting | 4 |
per il | 4 |
effective antiretroviral | 4 |
blood biomarkers | 4 |
obliterans syndrome | 4 |
giusto contesto | 4 |
con diametro | 4 |
clinical relevance | 4 |
least months | 4 |
concordantly negative | 4 |
candida albicans | 4 |
visceral leishmaniasis | 4 |
neutrophil counts | 4 |
increased bal | 4 |
assess outcomes | 4 |
peripheral airways | 4 |
chemotactic factors | 4 |
patient management | 4 |
il pattern | 4 |
acute exacerbation | 4 |
protein concentrations | 4 |
comparsa di | 4 |
undetectable bal | 4 |
inflammatory syndrome | 4 |
nervous system | 4 |
sample input | 4 |
dry cough | 4 |
ubiquitin ligase | 4 |
control study | 4 |
limited number | 4 |
culture negative | 4 |
testing within | 4 |
clavulanate acid | 4 |
procedures performed | 4 |
microbial agent | 4 |
low blood | 4 |
asthmatic horses | 4 |
patients present | 3 |
multiple targets | 3 |
nile red | 3 |
increased serum | 3 |
atopic group | 3 |
microbiological analysis | 3 |
polmonite organizzante | 3 |
pcp develop | 3 |
experimental infection | 3 |
recovery rate | 3 |
better understanding | 3 |
primer pair | 3 |
positive respiratory | 3 |
quando le | 3 |
di biopsie | 3 |
assessment score | 3 |
retrospective nature | 3 |
rna viral | 3 |
low lymphocyte | 3 |
supraphysiologic gm | 3 |
symptomatic patients | 3 |
valuable tool | 3 |
multiorgan failure | 3 |
distinct risk | 3 |
il tipo | 3 |
mg orally | 3 |
interstiziali idiopatiche | 3 |
obstructive lung | 3 |
graft dysfunction | 3 |
epidemiological studies | 3 |
severity pcp | 3 |
fungal pcr | 3 |
nine patients | 3 |
airway cellularity | 3 |
clinical setting | 3 |
genetic basis | 3 |
qrefcx values | 3 |
utili per | 3 |
nella fase | 3 |
respiratory bacterial | 3 |
si associa | 3 |
primary hiv | 3 |
replicates tested | 3 |
polmone sono | 3 |
bronchoscopic evaluation | 3 |
using molecular | 3 |
gli autori | 3 |
meno di | 3 |
immune dysregulation | 3 |
panel reporting | 3 |
corticosteroid therapy | 3 |
might explain | 3 |
cigarette smoke | 3 |
gina guidelines | 3 |
time frame | 3 |
increased respiratory | 3 |
hematological patients | 3 |
high morbidity | 3 |
weeks prior | 3 |
mycological criterion | 3 |
heart rate | 3 |
il reperto | 3 |
parenchima polmonare | 3 |
bal eseguito | 3 |
travel expenses | 3 |
infected adults | 3 |
significantly affected | 3 |
total nucleic | 3 |
mortality attributable | 3 |
possono anche | 3 |
therapy might | 3 |
important cause | 3 |
test order | 3 |
viruses detected | 3 |
false negatives | 3 |
streptococcus mitis | 3 |
quantitative bacterial | 3 |
mould disease | 3 |
pazienti che | 3 |
simultaneous acute | 3 |
reference standard | 3 |
di ii | 3 |
fluid alveolitis | 3 |
del surfactante | 3 |
biochemical tests | 3 |
antimicrobial use | 3 |
dust exposure | 3 |
liver function | 3 |
con conseguente | 3 |
events collected | 3 |
data presented | 3 |
per cui | 3 |
cough syndrome | 3 |
increased tracheal | 3 |
pneumococcal diseases | 3 |
colorazione di | 3 |
serum levels | 3 |
controllo della | 3 |
high number | 3 |
comparative analysis | 3 |
procedura diagnostica | 3 |
practical approach | 3 |
lo stesso | 3 |
bacterial etiology | 3 |
result might | 3 |
rv testing | 3 |
ph test | 3 |
portable lung | 3 |
royal brompton | 3 |
microbiological data | 3 |
like symptoms | 3 |
forme infettive | 3 |
subgroup analysis | 3 |
sia ritenuta | 3 |
di campioni | 3 |
della percentuale | 3 |
standard procedures | 3 |
ems including | 3 |
probable lrti | 3 |
oxygen saturation | 3 |
hanno ottenuto | 3 |
bronchial aspirate | 3 |
performed within | 3 |
airway epithelium | 3 |
infections cooperative | 3 |
cells per | 3 |
whereas bal | 3 |
mannheimia haemolytica | 3 |
less useful | 3 |
routinely scheduled | 3 |
product instructions | 3 |
i campioni | 3 |
serum albumin | 3 |
nodular infiltration | 3 |
reduced mortality | 3 |
hemorrhagic shock | 3 |
samples using | 3 |
da pneumocystis | 3 |
panel bin | 3 |
prognostic significance | 3 |
immunocompromised hosts | 3 |
median bal | 3 |
polymicrobial bal | 3 |
forced oscillation | 3 |
also evaluated | 3 |
laboratory features | 3 |
pulmonary lesions | 3 |
healthy controls | 3 |
greatest experience | 3 |
coccidioides immitis | 3 |
drug resistance | 3 |
da inalazione | 3 |
antimicrobial peptide | 3 |
negative pn | 3 |
using different | 3 |
pulmonary inflammation | 3 |
hypoxemic patients | 3 |
mdr tuberculosis | 3 |
nonspecific interstitial | 3 |
organizzazione endoalveolare | 3 |
shorter duration | 3 |
varicella zoster | 3 |
without respiratory | 3 |
subject groups | 3 |
monocytes macrophages | 3 |
steroid treatment | 3 |
different methods | 3 |
nasopharyngeal secretions | 3 |
sputum induction | 3 |
selection bias | 3 |
acute leukemia | 3 |
diffusion capacity | 3 |
pneumonia using | 3 |
drug users | 3 |
prism software | 3 |
factor receptor | 3 |
grade systemic | 3 |
controls showed | 3 |
immune dysfunction | 3 |
positive detections | 3 |
diabetes mellitus | 3 |
di questa | 3 |
vital capacity | 3 |
hiv load | 3 |
following bmt | 3 |
procedura tblb | 3 |
much higher | 3 |
bal findings | 3 |
among others | 3 |
immunofluorescent assay | 3 |
cellule giganti | 3 |
aspetti di | 3 |
il materiale | 3 |
support used | 3 |
quando si | 3 |
urt specimen | 3 |
multiple organ | 3 |
di laboratorio | 3 |
eosinophils may | 3 |
gastrointestinal tract | 3 |
microbiological information | 3 |
flow oxygen | 3 |
patients based | 3 |
il rischio | 3 |
laboratory data | 3 |
acvim consensus | 3 |
prevalente fenotipo | 3 |
marneffei infection | 3 |
performed routinely | 3 |
ethical standards | 3 |
oral thrush | 3 |
asthma development | 3 |
positive detection | 3 |
anche nel | 3 |
flexible bronchoscope | 3 |
discrepant results | 3 |
un indice | 3 |
forced vital | 3 |
common bacteria | 3 |
major role | 3 |
factors independently | 3 |
initial empiric | 3 |
di alveolite | 3 |
antiviral initiation | 3 |
cooperative group | 3 |
serum lactate | 3 |
culture positive | 3 |
probable possible | 3 |
colony forming | 3 |
good usefulness | 3 |
dei campioni | 3 |
di reflusso | 3 |
rsv detected | 3 |
much lower | 3 |
tpa ratio | 3 |
pp diagnosis | 3 |
radiological features | 3 |
previous reports | 3 |
vulnerable population | 3 |
type levels | 3 |
antigen tests | 3 |
contains supplementary | 3 |
drug regimen | 3 |
drug toxicity | 3 |
clinical studies | 3 |
approximately min | 3 |
serum immunoglobulin | 3 |
infected patient | 3 |
infezioni opportunistiche | 3 |
conventional culture | 3 |
fungal diagnosis | 3 |
uno studio | 3 |
randomised controlled | 3 |
whole blood | 3 |
ottenuti con | 3 |
per non | 3 |
neutrophil count | 3 |
also negative | 3 |
local immune | 3 |
less common | 3 |
influenza pneumonia | 3 |
endobronchial biopsy | 3 |
elucidated yet | 3 |
spectrum antibiotics | 3 |
global burden | 3 |
total cell | 3 |
neutrophil activation | 3 |
acquired lung | 3 |
essere effettuate | 3 |
racing thoroughbreds | 3 |
total protein | 3 |
discordant pairs | 3 |
dna detectable | 3 |
atypical bacterial | 3 |
endodontic infections | 3 |
pulmonary embolism | 3 |
ad alcuni | 3 |
authorized users | 3 |
immunosuppressed hiv | 3 |
demographic characteristics | 3 |
studio retrospettivo | 3 |
screening tests | 3 |
clinical picture | 3 |
panel semiquantitative | 3 |
multiple logistic | 3 |
esterno di | 3 |
lavage fluids | 3 |
con sintomi | 3 |
sono il | 3 |
may cause | 3 |
cells mm | 3 |
agglutination technique | 3 |
patient subgroups | 3 |
fluid strem | 3 |
disseminated disease | 3 |
cmv viral | 3 |
infected population | 3 |
pressure support | 3 |
cellule mononucleate | 3 |
underlying inflammatory | 3 |
differential effects | 3 |
survival advantage | 3 |
clinical manifestations | 3 |
extrinsic allergic | 3 |
biopsy diagnosis | 3 |
clinically insignificant | 3 |
brompton hospital | 3 |
among subjects | 3 |
lo sviluppo | 3 |
adjunctive steroid | 3 |
culture quantitation | 3 |
disease society | 3 |
molecular biomarkers | 3 |
increased sensitivity | 3 |
immunosuppressed children | 3 |
supplementary information | 3 |
bal con | 3 |
atopic status | 3 |
effector cells | 3 |
neutrophil numbers | 3 |
cell surface | 3 |
authors read | 3 |
frequently identified | 3 |
alcohol consumed | 3 |
csf knockout | 3 |
tests may | 3 |
working group | 3 |
si sono | 3 |
higher cd | 3 |
symptomatic lung | 3 |
distinguish normal | 3 |
obliterans organizing | 3 |
increased frequency | 3 |
respiratory resistance | 3 |
pneumonia may | 3 |
di anni | 3 |
oxygen delivery | 3 |
feasibility study | 3 |
invasive mould | 3 |
higher bal | 3 |
prothrombotic state | 3 |
specimens enrolled | 3 |
may result | 3 |
every case | 3 |
activator inhibitor | 3 |
specific genetic | 3 |
inalazione di | 3 |
mixed models | 3 |
i valori | 3 |
thoracic imaging | 3 |
percentuale di | 3 |
true pathogen | 3 |
adverse outcomes | 3 |
commonly reported | 3 |
antibody detection | 3 |
determined using | 3 |
bacterial growth | 3 |
residual volume | 3 |
una phmetria | 3 |
free days | 3 |
spectrum agents | 3 |
severely injured | 3 |
may take | 3 |
developing severe | 3 |
false positives | 3 |
mild pcp | 3 |
turnaround times | 3 |
among bal | 3 |
ketamine xylazine | 3 |
cell hyperplasia | 3 |
less experienced | 3 |
racing performance | 3 |
clinical course | 3 |
lung tumors | 3 |
sample set | 3 |
higher percentage | 3 |
human asthmatics | 3 |
also positive | 3 |
contrived polymicrobial | 3 |
necrosis factor | 3 |
nuclear factor | 3 |
culture reported | 3 |
per lo | 3 |
pcr tests | 3 |
respiratory effort | 3 |
seguenti patologie | 3 |
phase proteins | 3 |
di tipo | 3 |
clinical microbiology | 3 |
lrt symptoms | 3 |
missing data | 3 |
esiste una | 3 |
constitutional symptoms | 3 |
coronavirus strains | 3 |
results suggest | 3 |
il balf | 3 |
unknown cause | 3 |
th responses | 3 |
significantly decreased | 3 |
naturally occurring | 3 |
cells expressing | 3 |
cycle regulation | 3 |
lung cancer | 3 |
pulmonary symptoms | 3 |
bilateral interstitial | 3 |
bordetella bronchiseptica | 3 |
children date | 3 |
antigen test | 3 |
intergenic spacer | 3 |
valore predittivo | 3 |
study patients | 3 |
state hershey | 3 |
airway cough | 3 |
neutrophil chemotactic | 3 |
stato di | 3 |
parenchimale polmonare | 3 |
might allow | 3 |
detection methods | 3 |
methods compared | 3 |
idiopathic pneumonia | 3 |
data analysis | 3 |
dien bard | 3 |
triggering factors | 3 |
corresponding author | 3 |
hospital admission | 3 |
sviluppo di | 3 |
springer nature | 3 |
di ml | 3 |
among specimens | 3 |
together researchers | 3 |
score version | 3 |
alternative molecular | 3 |
diagnostic performances | 3 |
approximately ml | 3 |
cellule totali | 3 |
specific biomarker | 3 |
identify patients | 3 |
hrct scans | 3 |
results showed | 3 |
experienced physicians | 3 |
pulmonary immune | 3 |
nel sovranatante | 3 |
lung inflammation | 3 |
wash samples | 3 |
staphylococcus spp | 3 |
di infezione | 3 |
il suo | 3 |
performance data | 3 |
sectional area | 3 |
early life | 3 |
hopkins hospital | 3 |
fungal detection | 3 |
cytology profile | 3 |
stable asthmatics | 3 |
stable asthma | 3 |
metodica di | 3 |
tissue specimens | 3 |
dello strumento | 3 |
slightly higher | 3 |
malassezia infections | 3 |
standard methods | 3 |
della ventilazione | 3 |
national heart | 3 |
panel targets | 3 |
experimental asthma | 3 |
patients demonstrated | 3 |
pulmonary resistance | 3 |
decisioni terapeutiche | 3 |
model analysis | 3 |
pneumonia molecular | 3 |
polmonite organizzativa | 3 |
infectious etiology | 3 |
metapneumovirus infection | 3 |
laboratory markers | 3 |
study cohort | 3 |
persistent disease | 3 |
adjunctive therapy | 3 |
severe cases | 3 |
fungal burden | 3 |
dose tmp | 3 |
mtssu rrna | 3 |
fold increased | 3 |
negative targets | 3 |
em cell | 3 |
time quantitative | 3 |
lymphoid cell | 3 |
neutropenic patients | 3 |
decreased fibrinolysis | 3 |
times daily | 3 |
nodular infiltrates | 3 |
cui il | 3 |
delle pneumopatie | 3 |
daily dose | 3 |
anche nella | 3 |
bal possono | 3 |
innate immunity | 3 |
performed according | 3 |
plasma thrombin | 3 |
complication rates | 3 |
lung lobe | 3 |
ritenuta necessaria | 3 |
prevention strategies | 3 |
study site | 3 |
panel will | 3 |
labored breathing | 3 |
predominant pathogen | 3 |
sas institute | 3 |
studies using | 3 |
racing industry | 3 |
alcuni macrofagi | 3 |
quei pazienti | 3 |
della deglutizione | 3 |
radiographic changes | 3 |
fluid bronchoalveolar | 3 |
clinical samples | 3 |
pneumonia clinical | 3 |
cells obtained | 3 |
odds model | 3 |
predominant airway | 3 |
positive testing | 3 |
institutional affiliations | 3 |
cmv reactivation | 3 |
community acquired | 3 |
highly unlikely | 3 |
lrt specimens | 3 |
radiographs showed | 3 |
significance cutoff | 3 |
considered concordant | 3 |
high doses | 3 |
microbiol infect | 3 |
infections date | 3 |
chest high | 3 |
upstream regulators | 3 |
primary pulmonary | 3 |
practice guideline | 3 |
may improve | 3 |
pulmonary cytomegalovirus | 3 |
fastidious growth | 3 |
considered statistically | 3 |
solitary nodule | 3 |
may need | 3 |
soprattutto nei | 3 |
clinical cases | 3 |
antiviral properties | 3 |
reasonably ruled | 3 |
empirical antibiotics | 3 |
published maps | 3 |
ventilation group | 3 |
regression models | 3 |
non hanno | 3 |
term follow | 3 |
healthy individuals | 3 |
viral activity | 3 |
radiologic infiltrate | 3 |
cronica di | 3 |
potential confounders | 3 |
tract pathogens | 3 |
related morbidity | 3 |
tale sede | 3 |
appropriate antimicrobial | 3 |
nella conta | 3 |
ii tipo | 3 |
injured patients | 3 |
major source | 3 |
blood institute | 3 |
incidence plots | 3 |
early recognition | 3 |
empiric treatment | 3 |
tissue inhibitors | 3 |
culture based | 3 |
reporting protocols | 3 |
test di | 3 |
bal il | 3 |
th cytokine | 3 |
oxidative stress | 3 |
immunofluorescence staining | 3 |
host immunity | 3 |
radiographic abnormality | 3 |
reflusso gastro | 3 |
whether gm | 3 |
ricorso alla | 3 |
nature remains | 3 |
ccl mcp | 3 |
adult inpatients | 3 |
evidence suggesting | 3 |
pinze di | 3 |
pcr products | 3 |
hsct patients | 3 |
interleukin receptor | 3 |
significantly differ | 3 |
flow rate | 3 |
performing bal | 3 |